Where to Put Your High-End Medical Devices Plant: Vietnam or Singapore?

Short answer: For high-end medical devices (imaging diagnostics, surgical robots, implantables), the most important question is not “where is it cheap to build” but “where the product may be sold, and after how long.” The regulatory pathway — risk classification, marketing authorisation, clinical trials — decides time-to-market, and each country runs its own pathway. This article works through Vietnam’s legal framework (as of 18 October 2026) against Singapore’s at a high level.

1. Regulatory Pathway: The Map to Draw Before Choosing Land

Medical devices are not consumer goods: the product must be authorised for circulation by the regulator before sale. Three key nodes:

• Risk classification: devices are classified by risk level (low to high: e.g. consumables → diagnostic equipment → implantables). Higher risk means a heavier dossier (clinical trials, biocompatibility assessment…). Misclassification at the start forces the whole pathway to be redone.
• Marketing authorisation: in Vietnam, medical devices must obtain a circulation registration number under Decree No. 98/2021/ND-CP on medical device management (and its amending documents). The dossier includes technical documentation, quality certification (ISO 13485 is the common quality-management standard for medical devices) and test results.
• Clinical trials: high-risk, novel-technology devices usually need clinical-trial data. Where the trial runs, to which standard, and whether other regulators recognise it — must be calculated before siting the plant, because it affects R&D and manufacturing location choices.

The crux: the regulatory pathway in the producing country and in the destination market are two different pathways. A plant in Vietnam still needs separate registration procedures when selling into each market (US, EU, Japan…), and vice versa.

2. Vietnam’s Legal Framework for a Medical-Devices Plant

• Investment: The Law on Investment No. 143/2025/QH15 (effective 1 March 2026) + Decree No. 96/2026/ND-CP — IRC issuance. Hi-tech medical-device manufacturing is an encouraged sector.
• Medical device management: Decree No. 98/2021/ND-CP (and amending documents) — classification, marketing authorisation, manufacturing-establishment conditions. Manufacturers must meet conditions on personnel, facilities and quality management systems (ISO 13485 widely applied).
• Land: The Land Law No. 31/2024/QH15 (effective 1 August 2024) — land lease inside industrial parks; Decree No. 35/2022/ND-CP. High-end device plants need cleanrooms and electrostatic control — similar to pharma plants but with different line requirements (precision assembly, calibration).
• Environment: The Law on Environmental Protection No. 72/2020/QH14 — environmental impact assessment / environmental licence depending on scale and processes (component plating, painting, cleaning chemicals).
• Labor: the 2019 Labor Code; high-end devices need precision engineers and calibration specialists — a narrower talent pool than consumer electronics. Decree No. 219/2025/ND-CP (effective 7 August 2025) for foreign specialists.
• Tax: 20% CIT + incentives (hi-tech medical devices may qualify); the global minimum tax (Resolution No. 107/2023/QH15) if the threshold is exceeded.
• Intellectual property: high-end devices often carry patents (mechanisms, diagnostic algorithms). Protection under the IP Law; patent filing should run in parallel with product development.

3. Three Comparison Axes

Axis 1 — Product registration pathway: Vietnam: classification + marketing authorisation under Decree 98/2021 (as amended); review timelines vary by device type. Singapore: the Health Sciences Authority (HSA) registration system following the international risk-classification framework — rated transparent and predictable. For globally targeted products, add each destination’s pathway (FDA, CE…) to the calculation.

Axis 2 — Testing and calibration ecosystem: high-end devices need qualified testing labs, accredited calibration centres and partner hospitals for clinical trials. Singapore has this ecosystem ready; Vietnam’s is developing — some specialised tests may need to go abroad, costing time and money.

Axis 3 — Precision technical talent: precision mechanical engineers, biomedical-electronics engineers, ISO 13485 QA specialists. Singapore’s supply is deeper; Vietnam needs a long-term training-and-retention strategy plus foreign specialists in the early phase.

Singapore’s framework is high-level only; details to be checked by local counsel.

4. Worked Scenario: Diagnostic Imaging Equipment

Suppose you make premium ultrasound diagnostics, selling in Vietnam, ASEAN and targeting the EU:

• Step 1: Classify the device’s risk under Vietnamese regulations (Decree 98/2021 as amended) — determine what the marketing-authorisation dossier needs (clinical data or not).
• Step 2: For Vietnam: IRC, medical-device manufacturing-establishment conditions, product marketing authorisation, park land (cleanrooms, electrostatic control), an ISO 13485 QMS.
• Step 3: Map the destination-market registration pathway (EU: CE marking under the EU medical-device rules) — time and cost in parallel with the Vietnam pathway.
• Step 4: Staffing plan: calibration engineers, ISO 13485 QA specialists — domestic hires plus foreign specialists (work permits under Decree 219/2025).

5. First-30-Days Checklist

1. Classify device risk under current regulations — fix the registration pathway.
2. Review medical-device manufacturing-establishment conditions (Decree 98/2021 as amended).
3. Define destination markets and each market’s registration pathway (time, cost).
4. Assess the testing/calibration ecosystem: what can be done domestically, what must go abroad.
5. Engage local counsel in Singapore to check the HSA registration pathway and manufacturing conditions.

6. Two Devices, Two Timelines: An Illustration

Contrast two products made in the same hypothetical plant to see how the pathway — not the building — drives the decision. Product X: a premium ultrasound probe — moderate risk, no implantable component; its marketing-authorisation dossier rests on electrical safety tests, software validation and biocompatibility data. Product Y: a cardiovascular stent — high risk, implantable; its dossier needs full clinical-trial data plus long-term material-safety evidence.

For Product X, the practical bottleneck is usually testing capacity: if the accredited lab that can run the required electromagnetic-compatibility and biocompatibility tests sits abroad, each test round adds weeks of shipping and scheduling on top of the lab’s own queue. The decision question is how many test rounds the Vietnam site can complete domestically — and whether the budget carries one or two extra rounds if the first fails.

For Product Y, the bottleneck is clinical evidence: which hospitals can run the trial, to which good-clinical-practice standard, and whether the destination-market regulator accepts data generated in Vietnam. That question must be answered before the plant location is fixed, because the answer may point the trial — and with it part of the early R&D staffing — to a different country than the factory.

The two products can share one building; they cannot share one timeline. Investors who map both pathways in the first 30 days discover the real decision variable: where does each product reach its first legal sale fastest, at acceptable cost? Land prices, incentives and construction quotes are all secondary to that date.

This article is for general reference only and does not replace legal advice for your specific case. Details of Singaporean law should be checked by local counsel before deciding.

Frequently Asked Questions

1. What does Decree 98/2021/ND-CP regulate for medical-device manufacturing?
Decree No. 98/2021/ND-CP (and its amending documents) governs medical-device management in Vietnam: risk-based classification, manufacturing-establishment conditions and marketing-authorisation procedures. Manufacturers must meet conditions on professional personnel, facilities and quality management systems. This is the sectoral legal framework running alongside the Law on Investment.

2. Is ISO 13485 mandatory?
ISO 13485 is the international quality-management standard for medical devices, widely applied and in practice usually required for marketing authorisation and export. Even where the text may not say “mandatory” in every case, a high-end device plant without ISO 13485 can hardly sell into strictly regulated markets.

3. Where are clinical trials for medical devices conducted?
It depends on device type and destination. High-risk, novel devices usually need clinical data; trials must follow good clinical practice and be accepted by the regulator. With Vietnam’s trial ecosystem still developing, some specialised trials may need to run abroad or seek cross-recognition — factor this into timelines and budgets.

4. How long does marketing authorisation take in Vietnam?
Depending on device risk classification and dossier quality. Low-risk devices move faster; implantables and novel technologies need deep technical review and can take longer. Start in parallel with plant construction rather than waiting for the plant to finish before filing.

5. Why is Singapore highly rated on medical-device regulation?
Singapore’s HSA registration system follows the international risk-classification framework and is rated transparent and predictable — businesses know upfront what the dossier needs and how long it takes. For high-end devices targeting global markets, pathway predictability is worth as much as production cost.

This article has been quality-reviewed by the FLAW AI Legal Council